文献速递免疫规划卫生政策与健康促进

加纳HPV疫苗引入的成本效果与预算影响预测

The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana.
PubMed 文献 · Vaccine · 2021-07-21

研究用UNIVAC模型预测加纳将HPV疫苗纳入国家免疫规划的成本效果与预算影响,比较仅9岁女孩常规接种与9岁常规加10-14岁一次性补种的策略。结果显示所有策略均具成本效果,以双价疫苗常规加补种最具优势。

要点

  • 加纳HPV疫苗接种相比不接种在所有评估场景中均具成本效果。
  • 双价疫苗9岁常规加10-14岁补种最具成本效果且占优。
  • 疫苗项目年均成本占2022年总免疫成本的11-15%。

核心结论

  • 在支付意愿至少为人均GDP 40%(881美元)时,加纳引入HPV疫苗在所有策略下均具成本效果。

研究设计与样本

  • 使用比例结果模型UNIVAC 1.4版,从政府与社会视角评估引入双价与四价疫苗的成本效果。
  • 模拟2022年起持续十个出生队列,采用学校(80%)与社区外展(20%)联合交付策略。
  • 比较9岁女孩单年龄队列与9岁常规加10-14岁一次性补种的多年龄队列策略,对照为不接种。

主要发现

  • 所有评估场景下加纳全国HPV疫苗接种相比不接种均具成本效果。
  • 最具成本效果且占优策略为双价疫苗9岁女孩常规接种加10-14岁一次性补种,政府视角每避免一个DALY成本158美元(95%可信区间19-280美元)。

关键数值与推荐

  • 成本效果阈值参考:支付意愿至少为人均GDP 40%(881美元)。
  • 双价疫苗常规加补种策略:每避免一个DALY成本158美元(95%可信区间19-280美元),政府视角。

临床怎么用

  • 优先考虑9岁女孩常规接种加10-14岁一次性补种的双价疫苗策略,因其最具成本效果且占优。
  • 引入一次性补种比仅常规免疫更具成本效益,但项目成本更高,需预算规划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cervical cancer is responsible for around one-quarter of all cancer deaths among Ghanaian women. Between 2013 and 2015, Ghana conducted a pilot of HPV vaccination among 10-14-year-old girls in four regions; however, the country has yet to introduce the vaccine nationally. This study projected the cost-effectiveness and budget impact of adding HPV vaccination into Ghana's national immunization program. METHODS: We used a proportional outcomes model (UNIVAC, version 1.4) to evaluate the cost-effectiveness of introduction with bivalent (Cervarix™) and quadrivalent (Gardasil®) vaccines from government and societal perspectives. Vaccine introduction was modeled to start in 2022 and continue over ten birth cohorts using a combined delivery strategy of school (80%) and community outreach (20%). We modeled vaccination in a single age cohort of 9-year-old girls vs. a multi-age cohort of 9-year-old girls (routine) and 10-14-year-old girls (one-time campaign) compared to no vaccination. Health outcomes included cervical cancer cases, hospitalizations, deaths, and disability-adjusted life years (DALYs). We applied a discount rate of 3% to costs and outcomes. All monetary units are reported in USD 2018. RESULTS: National HPV vaccination in Ghana was projected to be cost-effective compared to no vaccination in all scenarios evaluated. The most cost-effective and dominant strategy was vaccination among 9-year-old girls, plus a one-time campaign among 10-14-year-old with the bivalent vaccine ($158/DALY averted from the government perspective; 95% credible range: $19-$280/DALY averted). Projected average annual costs of the vaccine program ranged from $11.2 to $15.4 M, depending on strategy. This represents 11-15% of the estimated total immunization costs for 2022 ($100,857,875 based on Ghana's comprehensive Multi-Year Plan for Immunization, 2020-2024). DISCUSSION: Our model suggests that introducing HPV vaccination would be cost-effective in Ghana under any strategy when willingness-to-pay is at least 40% GDP per capita ($881). Inclusion of a one-time catch-up campaign is shown to create greater value for money than routine immunization alone but would incur greater program costs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vodicka E, Nonvignon J, Antwi-Agyei KO, et al. The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana. Vaccine. 2021. PMID: 34303563. doi:10.1016/j.vaccine.2021.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。